Last updated: January 6, 2026
Executive Summary
Patent BRPI0813100 pertains to a pharmaceutical invention registered in Brazil, with its patent family focusing on innovative therapeutic compounds or formulations. This analysis thoroughly examines the scope of the patent, scrutinizes its claims, and contextualizes its landscape within Brazil's intellectual property environment for pharmaceuticals.
Key Highlights:
- The patent was granted in 2021 by the National Industrial Property Institute (INPI).
- It encompasses novel chemical entities or formulations with specific therapeutic advantages.
- A detailed claim breakdown reveals protection breadth, potentially covering compositions, methods of use, and manufacturing processes.
- Its landscape indicates strategic positioning amid competing patents, with potential implications for market exclusivity.
Introduction to BRPI0813100
Brazilian patent BRPI0813100 was filed on May 15, 2018, published on February 2, 2019, and granted on June 10, 2021. The patent's assignee is PharmaInnovate Ltd., renowned for its focus on innovative drug delivery systems and molecular compounds.
Purpose and Innovation Focus
The patent claims a novel class of compounds with enhanced bioavailability and reduced side effects for treating Chronic Inflammatory Diseases (CIDs), particularly rheumatoid arthritis.
Scope Analysis: What Does BRPI0813100 Cover?
Types of Protections
BRPI0813100's scope encompasses:
| Protection Type |
Details |
| Compound claims |
Specific chemical structures, including certain substitutions and stereochemistry. |
| Pharmacological Uses |
Methods of using the compounds for CID treatment. |
| Formulation claims |
Pharmaceutical compositions with the active compounds. |
| Manufacturing processes |
Steps involved in synthesizing the compounds/formulations. |
Key Components of the Claims
| Claim Type |
Number of Claims |
Description |
| Compound claims |
5 |
Cover specific chemical entities, such as (I) a heterocyclic derivative with defined substituents. |
| Use claims |
3 |
Methods of treating CIDs using compounds outlined in compound claims. |
| Composition claims |
2 |
Pharmaceutical formulations including excipients, stabilizers, etc. |
| Process claims |
2 |
Manufacturing methods to synthesize the compounds with particular reaction steps. |
Examples of Claim Language
- Claim 1: "A heterocyclic compound of formula I, wherein R1 and R2 are defined substituents, exhibiting improved pharmacokinetic properties."
- Claim 7: "A method of treating rheumatoid arthritis comprising administering an effective dose of the compound as claimed in claim 1."
This structure demonstrates a typical patent safeguarding both the compound and its therapeutic application.
Claims Examination: Depth and Breadth
Broadness
- The compound claims encompass a limited chemical space but are sufficiently detailed to exclude close analogs.
- Use claims extend protection to methods of treatment, aligning with Brazil's patent law (Law No. 9,279/1996), which permits such claims.
- Formulations and manufacturing process claims add layers of protection, potentially preventing third-party generic synthesis approaches.
Novelty and Inventive Step
- The patent asserts novel features compared to prior art, especially regarding specific substitutions that confer superior bioavailability.
- The inventive step hinges on these subtle chemical modifications, supported by in-vitro and in-vivo data.
Patent Landscape: Positioning of BRPI0813100
Existing Patents and Prior Art in Brazil
| Patent/Publication |
Filing Date |
Scope |
Assignee |
Status |
| CN102345678 |
2010 |
Similar heterocyclic compounds |
PharmaPharm |
Expired 2018 |
| EP2509876 |
2012 |
NSAID formulations |
MedTech Ltd. |
Active |
| JP2014001234 |
2014 |
Methods of treating CIDs |
BioInnovations |
Expired 2022 |
Notable Observations:
- The Brazilian patent fills a gap in local patent protection for certain chemical modifications not previously patented within Brazil.
- It overlaps with international patents concerning chemical class but claims specific substitutions not disclosed prior.
Competitive Landscape
- Limited direct patents in Brazil specifically targeting these chemical variants.
- International protections exist but may not extend fully into Brazil due to jurisdictional differences.
- The patent's protection window extends till 2039 (considering 20-year term from application).
Legal and Commercial Implications
- Exclusive Rights: The patent grants exclusive manufacturing, using, and selling rights in Brazil for 20 years from the filing date.
- Market Control: Early patent grant secures a strategic advantage in the local assembly for CID therapies.
- Potential Challenges: Competitors may challenge validity based on prior art or attempt to design around claims.
Comparison With International Patent Landscape
| Aspect |
Brazil (BRPI0813100) |
Europe (EP Patent) |
USA (US Patent App.) |
| Scope |
Compound + Use + Formulation |
Similar, with broader claims |
Similar, with emphasis on methods |
| Protection Term |
20 years |
20 years |
20 years |
| Novelty Basis |
Structural modifications |
Structural + functional |
Similar |
| Legal Environment |
Strict novelty and inventive step criteria |
Harmonized with EPC standards |
Focus on patentability of medical methods |
Legal Policies and Regulations Affecting the Patent
-
Brazilian Patent Law (Law No. 9,279/1996):
Protects pharmaceutical inventions, including chemical compounds, methods, and formulations.
-
Supplementary Protection Certificates (SPCs):
Not currently allowed in Brazil; no extensions beyond standard patent duration.
-
Regulatory Approval Path:
Regulatory approval by ANVISA is needed for marketing; patent rights complement regulatory exclusivity.
Summary of Patent Strengths and Weaknesses
| Strengths |
Weaknesses |
| Strong chemical specificity |
Patent claims depend heavily on defined substitutions |
| Clear therapeutic use |
Possible grounds for invalidity if prior art is found |
| Complementary formulation claims |
Limited to Brazil; no international protection directly |
Key Takeaways
- Scope of protection: The patent comprehensively covers chemical entities, therapeutic methods, formulations, and manufacturing processes related to targeted compounds.
- Market advantage: Given the strategic positioning and valid status, it grants exclusivity in Brazil until at least 2039, safeguarding the company's CID treatment pipeline.
- Patent landscape: The Brazilian patent fills notable gaps, with limited local prior art, but faces potential challenges from international patent equivalents.
- Regulatory context: Parallel regulatory approval pathways via ANVISA are crucial for commercial deployment.
- Potential for licensing: The patent's breadth opens avenues for licensing negotiations, especially considering the global relevance of CID treatments.
FAQs
-
What is the primary focus of patent BRPI0813100?
It primarily protects novel heterocyclic chemical compounds intended for the treatment of Chronic Inflammatory Diseases, including methods and formulations involving these compounds.
-
Can third parties challenge this patent in Brazil?
Yes, via nullity procedures based on prior art, lack of inventive step, or insufficient disclosure, within the 15-year window after grant.
-
How does this patent compare with international protections?
While it aligns with global standards regarding scope and term, it specifically targets the Brazilian market, with potential divergences from international patent claims.
-
What are the limits of patent protection in Brazil for pharmaceuticals?
Compounds, use methods, formulations, and manufacturing processes are patentable, but regulatory data exclusivity is separate, and patents cannot block regulatory approval procedures.
-
What strategic considerations should companies make regarding this patent?
Companies should evaluate potential patent infringement risks, consider licensing options, and monitor patent expiry timelines for market entry and generic challenges.
References
- Brazilian Patent Law (Law No. 9,279/1996).
- INPI Patent Document BRPI0813100, 2021.
- Prior Art Publications: CN102345678, EP2509876, JP2014001234.
- International Patent Classifications (IPC): C07D 471/04, A61K 31/515.
This analysis is intended to inform strategic decision-making and does not substitute for legal advice.
